Navigation Links
Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
Date:9/1/2009

SCHAUMBURG, Ill., Sept. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of adenosine injection, USP, an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia. Sagent will offer this latex-free, preservative-free adenosine product in 6 mg per 2 mL single-dose glass vials for intravenous use.

"This launch expands upon the full line of prefilled adenosine syringes we introduced in 2007, providing caregivers an array of adenosine delivery options in cardiac care settings," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "Our 2 mL adenosine vial is the second product introduced from our collaboration with Strides Arcolab."

Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 25 injectable products for the U.S. market.

About Adenosine Injection, USP

Adenosine Injection, USP, is the generic equivalent of Astellas Pharma U.S., Inc.'s Adenocard(R), an antiarrhythmic commonly used in the treatment of paroxysmal supraventricular tachycardia, a rhythm disturbance of the heart, in critical care situations. Adenosine works by slowing the electrical conduction in the heart, slowing heart rate of normalizing heart rhythm.

Adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
2. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
3. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
4. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
5. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
6. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
7. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
8. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
9. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
10. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
11. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... COTTAGE, New York , February 23, 2017 /PRNewswire/ ... health implications arising from increasing caseload for varicose veins ... recorded across the globe are prompting the adoption of ... latest study on global endovenous laser therapy ... attention towards aftereffects of lifestyle choices and consequences of ...
(Date:2/23/2017)... Feb. 23, 2017  As National Nutrition Month ... the Company is helping people live healthier lives ... prescription savings programs in all 50 states including:  ... Program  and  California Prescription Assistance Program . ... Columbia University for nutritious eating habits: ...
(Date:2/23/2017)... YORK , February 23, 2017 ... end of day as four out of nine sectors finished ... one sector managed a flat closing. Major US indices were ... Composite ended the day at 5,860.63, slightly down by 0.09%; ... at 20,775.60; and the S&P 500 closed at 2,362.82, down ...
Breaking Medicine Technology:
(Date:2/23/2017)... MA (PRWEB) , ... February 23, 2017 , ... ... and Department of Justice jointly issued a letter to withdraw previous ... accordance with their gender identity. The guidance issued in May 2016 by the ...
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Hamlin ... to announce that they are sponsoring a raffle. Throughout the month of February, patients ... will receive a gift card for a dinner for two at the Cheesecake Factory. ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
Breaking Medicine News(10 mins):